How well does CA125 find ovarian cancer in GP care?
In UK primary care, CA125 ≥35 U/ml had high NPV but only about 10% PPV for ovarian cancer, and elevated values also flagged other cancers.
Source
The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study
What they did
Researchers studied 50,780 women who had CA125 tested in English primary care, linking results to cancer diagnoses. They estimated diagnostic accuracy at the conventional ≥35 U/ml cutoff and examined age-stratified performance and non-ovarian cancers.
What they found
Ovarian cancer incidence was 0.9%. At ≥35 U/ml, PPV was 10.1%, sensitivity 77%, specificity 93.8%, and AUC 0.92. Performance and cancer mix varied by age; elevated CA125 also related to non-ovarian cancers.
The limits
What it doesn't show
Observational EHR data cannot prove that changing CA125 thresholds or pathways improves survival, and symptom recording is incomplete.
Key terms
- CA125
- Cancer antigen 125 blood biomarker used to investigate possible ovarian cancer.
- PPV
- Positive predictive value—probability of disease given a positive test.
- NPV
- Negative predictive value—probability of no disease given a negative test.
- Sensitivity
- Proportion of true cases correctly identified by the test.
- AUC
- Area under the ROC curve summarizing discrimination across thresholds.
- Primary care testing
- Investigations ordered by general practitioners before specialist referral.
Flashcards
Want these cards to stick?
Save the deck to NoteFren and study it with spaced repetition.
Quiz yourself
In this primary-care cohort, PPV of CA125 ≥35 U/ml for ovarian cancer was about:
Common questions
What cutoff was evaluated?
The standard clinical cutoff of ≥35 U/ml.
Is a positive CA125 usually ovarian cancer?
No—PPV was about 10%, so most positives are not ovarian cancer.
Is a negative test reassuring?
NPV was very high (99.8%), though no test is perfect.
Why mention non-ovarian cancers?
Elevated CA125 can accompany other malignancies that clinicians should consider.
More on Diagnostic accuracy